Ian Lund

Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). 
Akhtar OS, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P. Leuk Lymphoma. 2019 Jul;60(7):1650-1655. doi: 10.1080/10428194.2018.1554862. Epub 2019 Jan 2. PMID: 30601100

Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study. 
Akhtar OS, Groman A, Singh A, Ghione P, Lund I, Hernandez-Ilizaliturri FJ, Torka P. Leuk Lymphoma. 2022 May;63(5):1127-1136. doi: 10.1080/10428194.2021.2012662. Epub 2022 Feb 13. PMID: 35152821

Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. 
Torka P, Akhtar OS, Reddy NM, Baysal BE, Kader A, Groman A, Nichols J, Mavis C, Tario JD, Block AW, Sait SNJ, Ghione P, Sundaram S, Przespolewski ER, Mohr A, Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley RN, Wallace PK, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ. Cancer. 2022 Apr 15;128(8):1595-1604. doi: 10.1002/cncr.34106. Epub 2022 Feb 14. PMID: 35157306 Clinical Trial.

Working practice of orthodontic therapists. 
Roberts-Harry D, Spencer J, Wiggins A, Dolan R, Cain S, McCanny C, Peers H, Rodway E, Forty M, Atherton G, Huntley P, Petrucci D, Aston L, Gale D, Lund I, Northover A, Dye S, Rodway E, Evans L, Meisner J, Long C, O'Malley A, O'Neill P, Stubbs J, Noske S, Hodge. J Orthod. 2011 Jun;38(2):151-2; discussion 152-3. PMID: 21818881